Understanding the Rare Breast Cancer Subtypes With Variations in Histopathology, Molecular Profiling, Clinical...

Area of Science:

• Oncology
• Pathology
• Medical Research

Background:

• Breast cancer exhibits significant heterogeneity in clinical behavior, morphology, and molecular patterns.
• Rare breast cancer subtypes present unique challenges in diagnosis, prognosis, and treatment response.
• Accurate identification of these rare subtypes is essential for effective patient management.

Purpose of the Study:

• To evaluate the clinical features, pathological criteria, and outcomes of patients with rare breast cancer subtypes.
• To analyze treatment strategies and survival data for distinct rare breast cancer entities.
• To emphasize the importance of recognizing rare breast cancer subtypes for personalized medicine.

Main Methods:

• Retrospective, observational, and descriptive study design.
• Analysis of 30 patients diagnosed with rare breast cancer subtypes between January 2019 and December 2024.
• Review of clinical data, pathological morphology, immunohistochemistry (IHC) results, and survival outcomes.

Main Results:

• Included rare subtypes: apocrine carcinoma (27%), metaplastic carcinoma (46%), mucinous adenocarcinoma (17%), lymphoepithelioma-like carcinoma (3%), and invasive ductal carcinoma with neuroendocrine differentiation (7%).
• Observed variations in mean age at diagnosis, tumor size, and receptor status (ER, PR, Her-2/neu) across subtypes.
• Mucinous adenocarcinoma demonstrated the most favorable prognosis among the studied rare breast cancer subtypes.

Conclusions:

• Rare breast cancer subtypes possess distinct clinical and pathological characteristics.
• Understanding these unique behaviors is vital for developing tailored treatment strategies.
• Improved patient management and outcomes can be achieved through the recognition of these rare tumors.